Fit and Glam
Get Started
Get Started
Get Started
Get Started

Compounded Tirzepatide, Semaglutide and Cagrisema are available as subcutaneous injections, delivered directly to your doorstep. It has the same active ingredients as the branded drugs.

Fit and Glam offers free Telehealth consultations, and if you qualify, the session can be converted into a full medical appointment for prescription.

What Body-Mass-Index (BMI) qualifies for GLP weight loss medications?

To be eligible, you must have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related medical condition such as high blood pressure, high cholesterol, heart disease, PCOS, Diabetes etc.

How do I take the drug?

Compounded Tirzepatide, Semaglutide and Cagrisema contains the same active GLP-1 ingredient found in branded medications. Qualified patients will be prescribed with the appropriate weigthloss kit, and our licensed provider will offer step-by-step instructions on how to inject it in the body as well as inform them about the proper dose adjustment.

What are the potential side effects?

Common side effects of compounded GLP-1 medication include nausea, vomiting, diarrhea, constipation, and decreased appetite. These side effects are usually mild and tend to decrease over time as your body adjusts to the medication.

How does Fit and Glam works?

Fit and Glam

Terms & Conditions

Telehealth Consent

Privacy Policy

  • Facebook
  • Instagram

Disclaimer: Fit and Glam is a wellness online telehealth platform that facilitates the provision of healthcare services by connecting its users with licensed doctors, compounding pharmacies, and other licensed healthcare institutions. Fit and Glam itself is neither a licensed clinic nor a licensed compounding pharmacy.

© 2025 • Fit and Glam

 

Loading Comments...
 

    • Subscribe Subscribed
      • Fit and Glam
      • Already have a WordPress.com account? Log in now.
      • Fit and Glam
      • Subscribe Subscribed
      • Sign up
      • Log in
      • Copy shortlink
      • Report this content
      • View post in Reader
      • Manage subscriptions
      • Collapse this bar